Comparison of two investigative assays for the complexed prostate-specificantigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL

Objectives. To determine the ability of complexed prostate-specific antigen (cPSA) levels to diagnose prostate cancer. Methods. Between September 1998 and March 1999, cPSA levels in 182 consecut ive patients with an abnormal digital rectal examination (DRE) or a total P SA (tPSA; Tandem-R assay) level greater than 4.1 ng/mL were examined. Level s of cPSA were measured by the Markit-M PSA-ACT (alpha(1)-antichymotrypsin) assay (cPSA-MM) and Bayer Immune 1 complexed PSA assay (cPSA-BI). Free PSA (fPSA) was measured by the Tandem-R free PSA assay. Results. Of the 140 patients with tPSA between 4.1 and 10.0 ng/mL, 116 were histologically confirmed as having benign tissue; the remaining 24 were di agnosed with prostate cancer. To ensure a 92% sensitivity of cancer detecti on, a cutoff value for the tPSA, cPSA-MM, and cPSA-BI assays of 4.8 ng/mL, 2.7 ng/mL, and 4.6 ng/mL, respectively, was determined. The percentage of n egative biopsies prevented at these cutoff (ie, specificity) values was 14% , 23%, and 24%. No significant differences among these three assays were fo und. At 92% sensitivity, the cutoff value for the fPSA/tPSA, fPSA/cPSA-MM, and fPSA/cPSA-BI ratios was 18%, 27%, and 18%, respectively. The specificit y was 35%, 49%, and 51%. No significant differences were found among these three fPSA ratios. Significant differences were noted between tPSA and the fPSA/cPSA-MM ratio and between tPSA and the fPSA/cPSA-BI ratio. No differen ces were seen among the other PSA parameters. Conclusions. No difference in the ability of cPSA levels to distinguish pro state cancer and noncancer was observed between cPSA-MM and cPSA-BI or betw een their fPSA ratios. Only the fPSA/cPSA-MM and fPSA/cPSA-BI ratios provid ed significantly enhanced diagnostic performance compared with tPSA. UROLOG Y 55: 700-704, 2000. (C) 2000, Elsevier Science Inc.